Cytox

Quick links to important sections

Cytox

Treatment option: Leukemia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cytox

Quick Facts: Cytox (Cytarabine)

Property Description
Active Ingredient Cytarabine (Cytosine Arabinoside)
Form Solution for injection, lyophilized powder
Pharmacological Class Pyrimidine Antimetabolite, Chemotherapeutic Agent
Common Use (General) Systemic control of rapidly dividing malignant cells
Origin Synthetic Nucleoside Analog

Cytarabine: Classification as an Antineoplastic Agent

Cytox is the trade name for the active ingredient Cytarabine, a powerful synthetic nucleoside analog used as a chemotherapeutic agent in oncology. This medicine is primarily classified as a pyrimidine antimetabolite, a pharmacological class defined by its unique action in disrupting the metabolic processes of cells. This classification is clinically recognized due to the drug's established efficacy against hematologic cancers. The drug is a single-agent product, also known scientifically as Cytosine Arabinoside or Ara-C. Cytarabine is a key medication used in treating hematologic malignancies. Cytarabine is often differentiated from other cytotoxic agents by its necessity for specific cellular activation, giving it a unique pharmacological profile.

Purpose and Physical Nature of the Drug

The overarching purpose of Cytarabine therapy is to serve as an effective antineoplastic agent by acting against rapidly dividing malignant cells. The essential benefit of this medicine is the systemic control of malignancy by exploiting the aggressive, uncontrolled multiplication inherent in cancer cells; for example, in scenarios requiring the rapid reduction of a proliferating cell population. The drug's mechanism involves interference with DNA synthesis, acting as a cytotoxic agent that attacks cells in the S-phase of the cell cycle. This mechanism specifically targets the core reproductive function of cancer cells.

Cytarabine is supplied as an injectable medication in the form of a solution for injection or a lyophilized powder that requires reconstitution. Administration is typically achieved through intravenous (IV) infusion or subcutaneous (SC) injection. A specialized variation, such as the liposomal suspension, exists for applications requiring a sustained-release effect. These physical forms ensure the active ingredient can be delivered precisely to achieve the maximum intended therapeutic effect.

Regulatory References

  1. NIH Drug Information Portal

What side effects are possible with Cytox?

Cytox: Possible side effects and safety information

The safety profile of Cytox (Cytarabine) is characterized by systemic effects inherent to its classification as a potent antineoplastic agent. Official regulatory documents classify adverse reactions based on their frequency and the physiological systems affected, providing a structured view of the medicine's risk.


Adverse Reaction Classification

Very Common adverse reactions (occurring in more than 1 in 10 patients) typically include myelosuppression (leukopenia, thrombocytopenia, and anemia), gastrointestinal effects (nausea, vomiting, stomatitis), fever, rash, and reversible hepatic dysfunction (elevated enzymes). Common reactions may include sepsis, pneumonia, anorexia, and hair loss (alopecia).

System-Organ Class (SOC) Focus Key Safety Characteristics
Blood and Lymphatic Profound myelosuppression, the most expected major toxicity.
Gastrointestinal Stomatitis, diarrhea, and gastrointestinal ulceration/necrosis.
Nervous System Risk of neurotoxicity, particularly with high-dose regimens.

Serious Adverse Reactions and Safety Constraints

The most serious events documented in regulatory labeling relate to the consequences of profound myelosuppression, which can lead to life-threatening infections and hemorrhage. High-dose treatment regimens are explicitly associated with increased risk of severe toxicities, including Cerebellar Toxicity (ataxia, dysarthria) and severe Necrotising Colitis. A distinct pattern, the Cytarabine Syndrome, often appears 6 to 12 hours after administration, characterized by fever and myalgia. Safety constraints require caution in patients with pre-existing hepatic impairment due to the potential for increased toxicity. The official label mandates frequent monitoring of blood cell counts and observation for signs of neurotoxicity throughout the course of treatment.

Overdose and Emergency Response

The official regulatory profile for Cytarabine overdose emphasizes severe systemic toxicities and the necessity of immediate supportive care, given that no specific antidote is known.

Documented Overdose Manifestations

Overdose or severe toxicity is primarily defined by profound bone marrow suppression, resulting in leukopenia, thrombocytopenia, and anemia. Other severe manifestations documented in regulatory labeling include severe gastrointestinal ulceration, necrotizing colitis, and potentially fatal CNS toxicity involving cerebral and cerebellar dysfunction, somnolence, and convulsions. Cardiomyopathy and Adult Respiratory Distress Syndrome (ARDS) are also documented as severe and potentially fatal outcomes.

When to Seek Urgent Help

Immediate medical attention is required for the onset of complications arising from bone marrow suppression, such as sepsis (due to granulocytopenia) or hemorrhage (due to thrombocytopenia), both of which are listed as potentially fatal outcomes. The drug must be ceased upon signs of severe toxicity. Acute cardiopulmonary arrest following administration, indicative of anaphylaxis, necessitates immediate emergency intervention and resuscitation. The regulatory profile notes that patients with impaired hepatic or renal function have an increased risk of CNS toxicity. Management is limited to symptomatic and supportive treatment, and close medical supervision in a facility equipped for continuous monitoring is mandatory.

Therapeutic Uses of Cytox

Quick Facts: Therapeutic Domains

  • May be used to manage certain malignant lymphomas and leukemias.
  • Intended for use in the treatment of specific breast carcinoma and ovarian adenocarcinoma.
  • An approved therapeutic option for multiple myeloma.
  • In pediatric patients, it is used for minimal change nephrotic syndrome after an inadequate response to corticosteroid therapy.

What Cytox Treats: Main Uses and Benefits

Cytox (cyclophosphamide) is a medication that serves as an established component in the comprehensive management of several serious health conditions. It is used as a therapy for a range of malignant diseases, often in combination with other treatments.

This medication may be used in the management of specific lymphomas, including Hodgkin's disease and non-Hodgkin's lymphoma, as well as multiple myeloma. It is also an indicated treatment for various leukemias, such as chronic lymphocytic leukemia. The drug is further utilized in the therapeutic regimens for certain solid tumors, including carcinoma of the breast, adenocarcinoma of the ovary, retinoblastoma, and neuroblastoma (disseminated disease).

Beyond its primary uses in oncology, Cytox is indicated for pediatric patients with minimal change nephrotic syndrome, particularly when there is a documented failure to adequately respond to or a demonstrated inability to tolerate adrenocorticosteroid therapy. In these domains, the treatment is intended to support the overall management of the condition and may help to address disease progression. Treatment decisions and duration should be determined in consultation with a qualified healthcare professional.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cytox (Cytarabine) — Official Regulatory Information

Eligibility Scope Populations for whom use is allowed (as stated in label): Adults and pediatric patients for its specific antineoplastic indications. Populations for whom use is contraindicated: Patients with known hypersensitivity to cytarabine or any component of the formulation; use is also contraindicated during pregnancy. For specialized intrathecal formulations, active meningeal infection is a prohibition.

Age-Related Eligibility Rules The safety and efficacy are not established in infants. Older adults should be monitored with particular attention due to potentially reduced tolerance for toxicity.

Condition-Specific Eligibility Rules Use requires caution in patients with pre-existing liver dysfunction or poor renal function. Therapy must be started cautiously in patients with pre-existing bone marrow suppression.

Pregnancy and Lactation Eligibility Status The medicine is contraindicated during pregnancy due to the risk of fetal harm. Women must not breastfeed while receiving treatment.

Eligibility-Related Restrictions Vaccination with a live vaccine should be avoided in patients receiving Cytarabine. Females of reproductive potential must be advised to use effective contraception during treatment.

Eligibility Classifications (High-Level) Eligibility severity classification (as defined in official documents): Contraindicated (Hypersensitivity, Pregnancy), Caution (Hepatic/Renal Impairment), Not Recommended (Lactation, Live Vaccines, Infants).

Connection to the overall eligibility profile Regulatory documents define who can and cannot use Cytox by establishing absolute contraindications concerning hypersensitivity and reproductive status, while simultaneously identifying patient populations (such as those with organ impairment or infants) where use is either restricted to cautionary status or formally not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following section summarizes the officially documented interactions for Cytox (cyclophosphamide), reflecting information found in regulatory labeling.

Pharmacokinetic Interactions (PK)

Cytox is a pro-drug activated by cytochrome P450 (CYP) enzymes, primarily CYP2B6. Concomitant use with agents that induce these enzymes, such as phenobarbital or phenytoin, may increase the conversion of Cytox to its active metabolites, potentially raising the risk of toxicity. Conversely, co-administration with CYP inhibitors, such as certain protease inhibitors (e.g., atazanavir, ritonavir), may reduce the formation of active metabolites, which could decrease Cytox efficacy. Monitoring is necessary for agents affecting these metabolic pathways.

Pharmacodynamic Interactions (PD)

Cytox can have additive effects when combined with other drugs sharing similar toxicities. Co-administration with other myelosuppressive agents increases the risk and severity of bone marrow suppression. The risk of cardiotoxicity may be heightened when Cytox is used alongside other cardiotoxic drugs, such as anthracyclines. Live virus vaccines should be avoided due to the immunosuppressive effect of Cytox, which may lead to vaccine-induced infection or an inadequate immune response.

Administration and Other Constraints

The official labeling specifies that Cytox should be administered in the morning to allow for the complete elimination of urotoxic metabolites before the patient rests, mitigating the risk of urinary tract toxicity. Caution is required in patients with pre-existing hepatic or renal impairment, as these conditions can alter the metabolism and clearance of Cytox and its metabolites, requiring careful assessment in the context of any interacting agent.

Mechanism of Action

The pharmacologically inactive parent compound, Cytox (cyclophosphamide), is widely distributed following systemic administration. Hepatic cytochrome P450 (CYP) enzymes, particularly CYP2B6, catalyze the initial biotransformation, converting the drug to 4-hydroxycyclophosphamide. This intermediate exists in equilibrium with its tautomer, aldophosphamide. Aldophosphamide is subsequently cleaved, releasing the highly reactive alkylating agent, phosphoramide mustard, and the toxic metabolite, acrolein.

Phosphoramide mustard, the primary biologically active agent, acts as an alkylating agent, forming covalent bonds with nucleophilic sites on DNA, primarily at the N-7 position of guanine residues. This interaction leads to the formation of intra- and inter-strand DNA cross-links. The formation of these irreversible cross-links disrupts DNA replication and RNA transcription, leading to genotoxic stress and subsequent activation of programmed cell death (apoptosis), primarily in rapidly proliferating cell populations. This intracellular cascade results in a systemic reduction of circulating lymphocytes and other high-turnover cells, modulating the physiological function of the hematopoietic and immune systems.

Dosage and Administration Information

Cytox, with the active ingredient Cytarabine, is administered exclusively through injection, as the medicine is not active when taken by mouth. The primary approved administration methods include intravenous (IV) infusion or injection, subcutaneous (SC) injection, and intrathecal (IT) injection for central nervous system use. The specific route and schedule depend entirely on the established treatment protocol.


Administration and Dosing Schedules

Cytarabine is used according to cyclic regimens that incorporate specific administration periods followed by planned rest intervals, differentiating between induction, consolidation, and maintenance phases. For standard induction, dosing typically involves 100 mg/m^2 administered daily for a defined number of days, given either as a continuous IV infusion or as an IV injection every 12 hours. High-dose protocols, often used for refractory disease, may involve larger amounts, such as 2 g/m^2 to 3 g/m^2, delivered via IV infusion over one to three hours. Maintenance regimens involve lower doses, typically 1 mg/kg to 1.5 mg/kg, administered once or twice weekly.

Formulation and Procedural Constraints

The formulation choice and preparation are subject to specific procedural and formulation constraints. For intrathecal or high-dose IV use, a preservative-free formulation is mandatory. The lyophilized powder must be reconstituted and may require further dilution using compatible IV solutions (e.g., 0.9% Sodium Chloride). A specialized 50 mg liposomal formulation is restricted to intrathecal use only, is administered undiluted, and requires concomitant dexamethasone therapy to manage local reactions. Pediatric patients may receive doses toward the higher end of the published ranges, while patients with organ impairment may require careful evaluation and potential dose modification. Administration is always conducted under the close supervision of a physician experienced with cytotoxic agents.

Recent Clinical Evidence

Cytox (cyclophosphamide) has been extensively studied, primarily as a foundational agent within standardized, multi-drug regimens for various cancers and other conditions. The research base relies on large-scale randomized controlled trials (RCTs) and Phase III combination studies.

For malignant lymphomas and leukemias, studies explored its role in complex protocols. Researchers studied high-level outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS), with reports describing specific measurements related to disease control. Similarly, for multiple myeloma, research examined its use in established combinations, reporting measurements of response rates and survival outcomes over defined follow-up periods. A primary limitation across these oncology indications is that the evidence is focused on the overall multi-drug regimen, meaning the isolated contribution of cyclophosphamide to the total measured outcome is not well characterized.

Evidence for pediatric minimal change nephrotic syndrome (MCNS) includes RCTs and long-term cohort studies. Researchers specifically studied outcomes such as remission achievement and the time until relapse in children with steroid-dependent disease. Findings describe patterns observed in these studies where certain patient groups were seen to have fewer subsequent relapses. However, for this pediatric indication, sample sizes were modest, and long-term effects are not fully established across the entire population. The overall research base requires ongoing study to address uncertainties regarding the optimal use patterns alongside newer therapies.

Key Studies & References

  1. NIH Drug Information Portal: Cyclophosphamide (General Classification and Use)
  2. Systematic Review of Combination Chemotherapy Protocols for Multiple Myeloma

Frequently Asked Questions (FAQ)

Common questions about Cytox (FAQ)

Q: What are the most common reasons people stop taking Cytox?

Regulatory documents list adverse reactions by frequency, such as myelosuppression, fever, and rash. The medical team determines when to modify or discontinue treatment based on the severity and type of toxicity experienced. Official documentation indicates that treatment decisions involve managing potential side effects while aiming to complete the prescribed regimen.

Q: Can Cytox be taken alongside common over-the-counter pain relievers?

Official labeling identifies potential interactions with medicines that share similar toxicities or affect the body's enzyme system. However, specific common over-the-counter pain relievers are not explicitly listed in the regulatory documents. It is important that your physician has a record of all medicines and products you use so treatment can be safely coordinated.

Q: Is there a generic version of Cytox available?

Yes, the active ingredient in Cytox, which is Cytarabine (also known as Cytosine Arabinoside), is available as a generic injection. The availability of a generic form is often noted in official health authority consumer information.

Q: What kind of studies support the use of Cytox?

Studies supporting the use of the medicine are extensive, primarily involving large-scale clinical research. These include Randomized Controlled Trials (RCTs) and Phase III combination studies, focusing on its effectiveness for various cancers and other conditions.

Q: What is the general success rate mentioned in the Cytox research?

Research documents report key measured outcomes such as Overall Survival (OS), Progression-Free Survival (PFS), and specific response rates. Official reports generally indicate that the isolated contribution of the medicine to the success of a multi-drug regimen is typically not characterized separately from the overall protocol.

Q: Is it necessary to finish the entire course of Cytox even if I feel better quickly?

Treatment with Cytox is given according to highly structured cyclic regimens, which include specific administration periods and planned rest intervals. Official labeling describes these cycles, which are intended to be followed precisely according to the physician's instructions.

Q: Does Cytox require special storage conditions?

Yes, official guidance specifies precise storage conditions for the medicine. Unopened vials must be stored at controlled room temperature (between 20 C and 25 C) and protected from light. If the medicine is opened or diluted, the solution typically requires refrigeration.

Q: What is the difference between Cytox and its active ingredient name?

Cytox is a trade or brand name for the medicine. Its active ingredient is Cytarabine, which is also scientifically known as Cytosine Arabinoside. Official documents often use the name Cytarabine when discussing the medicine's mechanism and properties.

Q: What if I experience a rare but listed side effect from Cytox?

The official label indicates that the medicine should be administered under the close supervision of a physician experienced in cytotoxic agents. Official patient information advises patients receiving this medicine to inform their healthcare team of all side effects, including rare ones.

Q: Is Cytox considered a long-term treatment option?

Treatment protocols are organized into distinct, pre-defined cyclic regimens (induction, consolidation, maintenance phases). The decision regarding the total number of cycles or the overall duration is based on the specific condition being treated and the patient's tolerance, as determined by the physician.

Q: Does Cytox affect energy levels or cause tiredness?

Yes, regulatory documents list fatigue or generally feeling tired or weak as a reported side effect, especially in certain treatment regimens. This is a common experience documented in official adverse reaction listings.

Q: Can Cytox cause problems with sleep?

Official adverse reaction reports indicate that insomnia (trouble sleeping) is listed as a possible side effect of the medicine.

Q: Is it common to have headaches when starting Cytox?

Yes, headache is a listed side effect of Cytox. This is often associated with high-dose regimens or with the specific collection of symptoms known as Cytarabine Syndrome.

Q: What should I know about taking Cytox if I have [a general organ condition, e.g., kidney issues]?

Official product information states that use requires caution in patients who have pre-existing liver or kidney impairment. These conditions can change how the body processes the medicine, and patients may require a careful evaluation or potential dose adjustment from their doctor.

Q: What happens if I miss a dose of Cytox?

Since Cytox is administered on a strict schedule, patients are advised to contact their medical team immediately for guidance, rather than attempting to adjust the schedule independently. You should not attempt to adjust your schedule without clinical direction.

Q: Is Cytox a type of antibiotic?

No. Cytox (Cytarabine) is officially classified as a Pyrimidine Antimetabolite, which is a type of powerful Chemotherapeutic Agent. It is not an antibiotic used to treat bacterial infections.

Q: What classification of medicine is Cytox?

Cytox is classified as a Pyrimidine Antimetabolite and a Chemotherapeutic Agent. This means it is a drug used in the treatment of cancer that works by interfering with the metabolic processes of rapidly dividing cells.

Q: Does Cytox have a 'Black Box Warning' listed by the FDA?

Yes, certain formulations of Cytarabine, such as the specialized liposomal suspension, are associated with a Boxed Warning from the FDA. This warning emphasizes the risk of severe reactions and the necessity for the medicine to be administered under the supervision of a qualified physician.

Q: Can Cytox affect my ability to get pregnant or father a child?

Regulatory documents indicate the medicine may impair fertility in both males and females. Patients should discuss family planning and sperm donation considerations with their physician.

Q: What are the possible long-term side effects associated with Cytox use?

While the most common side effects are acute and short-term, the regulatory documents note that in rare cases, the medicine can cause irreversible neurological dysfunction. Long-term follow-up studies are used to monitor the persistence of other effects like changes to reproductive function.

Q: Can I take vitamins while I am on Cytox?

Interactions with vitamins are not explicitly listed in the official labeling. However, the regulatory information warns against taking any agent that affects the body's CYP450 enzyme system or shares similar toxicities. It is important to inform your physician of all supplements and vitamins you use.

Q: How quickly does Cytox leave the system after stopping treatment?

In its systemic form, Cytarabine is rapidly eliminated from the body. The terminal half-life (the time it takes for half of the drug to be eliminated) is typically reported in the range of one to three hours.

Q: Can Cytox be cut or crushed if someone has trouble swallowing pills?

No, Cytox is not available as an oral tablet or capsule that can be cut or crushed. The medicine is supplied as an injection (solution or powder for injection) for administration via intravenous, subcutaneous, or intrathecal routes.

Q: What is the purpose of the different strengths Cytox is offered in?

The medicine is available in different strengths and dose amounts to support distinct treatment protocols. For example, a lower dose is used for maintenance therapy, while a much higher dose is used for induction or refractory disease treatment, depending on the regimen established by the physician.

Q: Does Cytox affect blood pressure?

Yes, official adverse reaction reports from clinical trials have listed both Hypotension (low blood pressure) and Hypertension (high blood pressure) as possible side effects.

Q: Are there any known interactions between Cytox and common vaccines?

Official labeling states that live virus vaccines should be avoided because of the immunosuppressive effect of Cytox. For common non-live vaccines, clinical oversight is required to determine the appropriate timing.

Q: If I have allergies, is Cytox still a suitable option?

The medicine is contraindicated (should not be used) in patients with known hypersensitivity to Cytarabine or any component in the formulation. All other non-drug related allergies should be discussed with the treating physician.

Q: Does Cytox interfere with blood sugar levels?

While not always explicitly listed as a primary side effect, clinical protocols often require monitoring of glucose levels during therapy. This suggests that the medicine may have the potential to interfere with blood sugar levels, requiring regular assessment by your healthcare team.

Q: What are the criteria for a person to be eligible for Cytox treatment?

Eligibility is defined by the medicine's approved indications (the diseases it is intended to treat) and the established exclusion criteria. Official documents define absolute contraindications (like pregnancy or hypersensitivity) and situations requiring caution (like organ impairment).

Q: Can taking Cytox change the way my senses (taste, smell) work?

Yes, official adverse reaction reports have included Dysgeusia (a distortion or change in the sense of taste) as a possible side effect in patients receiving combination regimens.

Q: Why is my doctor asking me about my full medication list before starting Cytox?

Official guidelines require a full medication list to identify potential pharmacokinetic (how the body processes the drug) and pharmacodynamic (additive toxicity) interactions. This is particularly important for agents that affect the body’s enzyme system or increase the risk of bone marrow suppression.

Q: Do studies suggest Cytox is more effective for certain patient groups?

Research has observed different patterns in specific patient groups, such as children with certain conditions or older patients in some trials. These groups may show differing tolerance levels or response rates, which informs the overall clinical approach.

Q: Are there any restrictions on driving or operating machinery while taking Cytox?

Adverse reactions such as dizziness, somnolence (drowsiness), and certain types of neurotoxicity are listed in the official safety profile. Because these effects are listed, patients should use caution regarding driving or operating machinery.

Q: Is it true that Cytox can interact with herbal supplements?

While specific herbal supplements are not usually listed, the official regulatory information warns against using any agent that affects the CYP450 enzyme system in the body. Many herbal supplements can interact this way, so they must all be discussed with your physician.

Q: Why is Cytox sometimes associated with [a common but vague side effect, e.g., stomach upset]?

The official documents list Gastrointestinal effects (such as nausea, vomiting, and mouth sores) as very common adverse reactions. This is associated with the medicine’s mechanism of action, which targets all rapidly dividing cells, including the cells lining the digestive tract.

Q: If I feel better, should I continue taking Cytox?

Official labeling indicates that treatment is based on structured, complete cycles designed by a physician. Patients are directed to adhere to the full administration schedule.

Q: Can Cytox cause weight gain or loss?

Official safety documents list decreased appetite (anorexia) as an adverse reaction in clinical trials. This is a side effect that may be associated with subsequent weight loss.

How should Cytox be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Cyclophosphamide must adhere to specific conditions mandated by regulatory labeling to maintain stability and ensure safe handling.

Product State Storage Temperature and Protection
Unopened Vials Controlled Room Temperature (20 C to 25 C); store in the original carton to protect from light.
Opened/Diluted Solutions Refrigerate at 2 C to 8 C.

Partially used vials must be refrigerated, and the remaining product must be discarded after 28 days [1.4]. Cyclophosphamide is a hazardous drug and must be kept out of the reach of children. All unused or expired product and related waste must be disposed of according to local procedures for cytotoxic agents, as disposal in household waste or the sewer is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cytox found in:

A-Z Index: